American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Endocrine Practice

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.4158/EP.9.6.544PMID 14715483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of oral pamidronate in preventing bone loss in postmenopausal women

  2005cited by this paper
• A prospective study of thiazide use and fractures in women

  2005cited by this paper
• The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

  2003cited by this paper
• The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

  2003cited by this paper
• The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

  2003cited by this paper
• V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women

  2002cited by this paper
• Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Treatment of osteoporosis with bisphosphonates.

  2001cited by this paper
• Antifracture efficacy of antiresorptive agents are related to changes in bone density.

  2000cited by this paper
• Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

  2000cited by this paper
• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

  2000cited by this paper
• Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

  2000cited by this paper
• Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

  2000cited by this paper
• Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.

  2000cited by this paper
• Clinical Use of Biochemical Markers of Bone Remodeling: Current Status and Future Directions

  2000cited by this paper
• Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients

  2000cited by this paper
• Upper gastrointestinal toxicity of alendronate

  2000cited by this paper
• Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.

  2000cited by this paper
• Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

  2000cited by this paper
• Monitoring Osteoporosis Therapy With Bone Densitometry: Misleading Changes and Regression to the Mean

  2000cited by this paper
• Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

  2000cited by this paper
• Prevention of hip fracture in elderly people with use of a hip protector.

  2000cited by this paper
• Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

  2000cited by this paper
• Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.

  1999cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• Understanding the Bone Mass Measurement Act.

  1999cited by this paper
• The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women

  1999cited by this paper
• Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency.

  1999cited by this paper
• Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group.

  1999cited by this paper
• Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

  1999cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial.

  1999cited by this paper
• [Esophagitis associated with the use of alendronate].

  1999cited by this paper
• Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.

  1999cited by this paper
• Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

  1999cited by this paper
• Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.

  1999cited by this paper
• EVIDENCE‐BASED MEDICINE AND OSTEOPOROSIS: A COMPARISON OF FRACTURE RISK REDUCTION DATA FROM OSTEOPOROSIS RANDOMISED CLINICAL TRIALS

  1999cited by this paper
• Therapy for fracture prevention.

  1999cited by this paper
• The clinical tolerability profile of alendronate.

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• Fluoride Salts are no Better at Preventing New Vertebral Fractures than Calcium-Vitamin D in Postmenopausal Osteoporosis: The FAVOStudy

  1998cited by this paper
• Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

  1998cited by this paper
• Risedronate

  1998cited by this paper
• Effect of Ipriflavone—a Synthetic Derivative of Natural Isoflavones—on Bone Mass Loss in the Early Years After Menopause

  1998cited by this paper
• Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

  1998cited by this paper
• The Effect of Sodium Monofluorophosphate plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis

  1998cited by this paper
• BIOCHEMICAL MARKERS OF BONE TURNOVER: Applications For Osteoporosis

  1998cited by this paper
• A Randomized Study of Tibolone on Bone Mineral Density in Osteoporotic Postmenopausal Women With Previous Fractures

  1998cited by this paper
• Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.

  1998cited by this paper
• Raloxifene

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary.

  1998cited by this paper
• Relationship between exercise and bone mineral density among over 5,000 women aged 40 years and above.

  1998cited by this paper
• Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  1998cited by this paper
• Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability

  1998cited by this paper
• Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

  1998cited by this paper
• Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation

  1997cited by this paper
• Short‐Term Intravenous Bisphosphonates in Prevention of Postmenopausal Bone Loss

  1997cited by this paper
• Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

  1997cited by this paper
• Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β‐Estradiol and Dydrogesterone

  1997cited by this paper
• Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

  1997cited by this paper
• Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

  1997cited by this paper
• Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.

  1997cited by this paper
• Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post‐menopausal osteoporosis

  1997cited by this paper
• Perimenopausal bone density screening--will it help prevent osteoporosis?

  1997cited by this paper
• Alendronate-associated esophagitis: endoscopic and pathologic features.

  1997cited by this paper
• Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

  1997cited by this paper
• Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

  1996cited by this paper
• Perspective slow‐release sodium fluoride in osteoporosis

  1996cited by this paper
• Axial Bone Mass in Older Women

  1996cited by this paper
• Cyclical pamidronate infusions in postmenopausal osteoporosis.

  1996cited by this paper
• Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

  1996cited by this paper
• Esophagitis associated with the use of alendronate.

  1996cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

  1996cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Bone-density measurement.

  1992cited by this paper
• Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

  1992cited by this paper
• Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.

  1980cited by this paper
• Calcitonin

  1968cited by this paper

• circCacna1c modulates osteogenic differentiation of BMSCs via miR-7669-3p/Ciart axis in osteoporosis.

  2025cites this paper
• Trabecular bone score in obese patients with and without diabetes

  2024cites this paper
• Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

  2024cites this paper
• Zoledronic Acid

  2023cites this paper
• Review of Osteoporotic Fractures: Occurrence, Prevention, and Consequences

  2023cites this paper
• Revisão sobre fraturas osteoporóticas: Ocorrência, prevenção e consequências

  2023cites this paper
• Optimization of the dosage regimen of zoledronic acid with a kinetic-pharmacodynamic model and exposure-response analysis

  2023cites this paper
• A Unique Patellar Tendon Rupture and Small Tibial Avulsion fracture in a Post-Menopausal Patient

  2022cites this paper
• Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis

  2021cites this paper
• Interdisciplinary Management of Bisphosphonate-Related Osteonecrosis of the Jaw

  2021cites this paper
• Growth hormone assays and dynamic tests in the diagnosis of acromegaly and GH deficiency in adults

  2021cites this paper
• Safety of non-hormonal medications for managing hot flashes

  2021cites this paper
• Bone health assessment in clinical practice is infrequenty performed in patients with chronic pancreatitis.

  2020cites this paper
• Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission

  2020cites this paper
• Reappraisal of microscopic microsurgical transsphenoidal surgery for GH-secreting pituitary macroadenoma in patients with acromegaly: Historical data from Vietnam (2010–2013)

  2020cites this paper
• Gentianae Macrophyllae Radix Water Extract Inhibits RANKL-Induced Osteoclastogenesis and Osteoclast Specific Genes

  2020cites this paper
• QingYan Formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways.

  2020cites this paper
• PTH and PTHrP Analogs: Treatment of Osteoporosis

  2020cites this paper
• Metformin Attenuates Osteoporosis in Diabetic Patients with Carcinoma in Situ: A Nationwide, Retrospective, Matched-Cohort Study in Taiwan

  2020cites this paper
• Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database

  2020cites this paper
• Identifying the Factors That Affect Depressive Symptoms in Middle-Aged Menopausal Women: A Nationwide Study in Korea

  2020cites this paper
• Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

  2020cites this paper
• Imaging of sacroiliac joints in patients with acromegaly

  2019cites this paper
• A Nutraceutical Approach to Menopausal Complaints

  2019cites this paper
• Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy

  2019cites this paper
• Gene co-expression network analysis identifies BRCC3 as a key regulator in osteogenic differentiation of osteoblasts through a β-catenin signaling dependent pathway

  2019cites this paper
• Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study

  2019cites this paper
• Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study

  2019cites this paper
• Study of Surface Mechanical Parameters on Composite Biological Structures by using Non-Destructive Optical Tests

  2019cites this paper
• Women in LOVe: Lacto-Ovo-Vegetarian Diet Rich in Omega-3 Improves Vasomotor Symptoms in Postmenopausal Women. An Exploratory Randomized Controlled Trial

  2019cites this paper
• Bone Regeneration Induced by Strontium Folate Loaded Biohybrid Scaffolds

  2019cites this paper
• Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey

  2019cites this paper
• Musculoskeletal Health and Healthy Ageing

  2019cites this paper
• Peptide TQS169 prevents osteoporosis in rats by enhancing osteogenic differentiation and calcium absorption

  2018cites this paper
• Testosterone and Cardiovascular Health

  2018cites this paper
• Osteoporosis‐Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately‐Insured Women in the United States, 2008–2014: An Observational Study

  2018cites this paper
• Prevention of low bone mass to achieve high bone density in Mexico: position of the Mexican Association for Bone and Mineral Metabolism

  2018cites this paper
• Assessment of bone turnover in osteoporosis: harmonization of the total testing process

  2018cites this paper
• Screening for osteoporosis: A systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines

  2018cites this paper
• Cortical bone quality affectations and their strength impact analysis using holographic interferometry.

  2018cites this paper
• Epigenetic Mechanisms in Osteoporosis

  2018cites this paper
• Bone Mineral Density Distribution Curves in Spanish Adults With Down Syndrome.

  2018cites this paper
• effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a phase ii study

  2018cites this paper
• Whole Body Vibration Exposure on Markers of Bone Turnover, Body Composition, and Physical Functioning in Breast Cancer Patients Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial

  2018cites this paper
• Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR.

  2018cites this paper
• Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults.

  2018cites this paper
• Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

  2018cites this paper
• Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study

  2018cites this paper
• Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management

  2017cites this paper
• One year of training with FES has impressive beneficial effects in a 36-year-old woman with spinal cord injury

  2017cites this paper
• Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study

  2017cites this paper
• The EuroMyositis registry: an international collaborative tool to facilitate myositis research

  2017cites this paper
• Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study

  2017cites this paper
• A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice

  2017cites this paper
• Live imaging of follicle stimulating hormone receptors in gonads and bones using near infrared II fluorophore

  2017cites this paper
• Goal‐Directed Treatment for Osteoporosis: A Progress Report From the ASBMR‐NOF Working Group on Goal‐Directed Treatment for Osteoporosis

  2017cites this paper
• 4 Self-Reported Prevalence of Osteoporosis in Australia

  2017cites this paper
• Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.

  2017cites this paper
• Hypertension in Women: Evaluation and Management.

  2016cites this paper
• Cost‐Effectiveness of Osteoporosis Screening Strategies for Men

  2016cites this paper
• Three-Dimensional Endoscopic Endonasal Approach and Outcomes in Sellar Lesions: A Single-Center Experience of 104 Cases.

  2016cites this paper
• Diosgenin prevents bone loss on retinoic acid-induced osteoporosis in rats

  2016cites this paper
• Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism

  2016cites this paper
• The deprescribing of calcium supplements in a state operated developmental center: a 10-year longitudinal pilot study

  2016cites this paper
• Clinician time used for decision making: a best case workflow study using cardiovascular risk assessments and Ask Mayo Expert algorithmic care process models

  2016cites this paper
• In silico profiling for secondary metabolites from Lepidium meyenii (maca) by the pharmacophore and ligand-shape-based joint approach

  2016cites this paper
• Osteoporosis Recovery by Antrodia camphorata Alcohol Extracts through Bone Regeneration in SAMP8 Mice

  2016cites this paper
• Controversies in osteoporosis management

  2016cites this paper
• Um caso de acromegalia: ver para além do óbvio

  2016cites this paper
• Pharmacologic Therapies in Women's Health: Contraception and Menopause Treatment.

  2016cites this paper
• Systemic Diseases and Conditions Affecting Jaws.

  2016cites this paper
• Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta‐analysis

  2016cites this paper
• Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.

  2016cites this paper
• Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

  2016cites this paper
• 17. Supplemental calcium use and vascular outcomes

  2016cites this paper
• Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.

  2016cites this paper
• Association of Respiratory Tuberculosis with Incident Bone Fracture: Bridging the Tuberculosis Airway Infection and the Osteoporotic Bone

  2016cites this paper
• The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model

  2016cites this paper
• REINVIGORATING THE OSTEOPOROSIS MESSAGE.

  2016cites this paper
• The knowledge and attitude of women in Kermanshah on Osteoporosis (2015)

  2016cites this paper
• The effect of boron on alveolar bone loss in osteoporotic rats

  2016cites this paper
• Epidemiology of Postmenopausal Osteoporosis and Related Risk Factors in Female Residents of Tashkent and Namangan (Republic of Uzbekistan)

  2016cites this paper
• Patterns of pharmacologic treatment in US patients with acromegaly

  2016cites this paper
• Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

  2016cites this paper
• Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis.

  2016cites this paper
• Diagnóstico bioquímico y morfológico:y algoritmo diagnóstico

  2016cites this paper
• Intraoperative Magnetic Resonance Imaging During Endoscopic Transsphenoidal Surgery of Growth Hormone-Secreting Pituitary Adenomas.

  2016cites this paper
• Management of Hyperglycemia in a Patient with Acromegaly Treated with Pasireotide LAR: A Case Study

  2016cites this paper
• Conjugated Linoleic Acid and Postmenopausal Women's Health.

  2015cites this paper
• Calcium and Vitamin D Supplementation

  2015cites this paper
• THE EFFECT OF CHOLESTEROL ON THE OSTEOBLAST RESPONSIVENESS TO HYDRODYNAMIC PRESSURE STIMULATION

  2015cites this paper
• The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis

  2015cites this paper
• Evidence-based approach to cutaneous hyperandrogenism in women.

  2015cites this paper
• Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

  2015cites this paper
• How Long to Treat with Bisphosphonates

  2015cites this paper
• A Comparative Study of the Effect of Thyme and Calcium with Vitamin D3 in Treatment of postmenopausal Women with Osteoporosis

  2015cites this paper
• Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient

  2015cites this paper
• Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.

  2015cites this paper
• Successful Conservative Treatment: Multiple Atypical Fractures in Osteoporotic Patients After Bisphosphate Medication

  2015cites this paper
• Need for improved monitoring in patients with acromegaly

  2015cites this paper